NSCLC HER3-DXd Breakthrough? Insights from Resistant Cases – HERTHENA-Lung02 Results Lung Cancer Treatment 3 Mins Read This report examines the NSCLC HER3-DXd breakthrough. It focuses on its potential impact on patients with resistant EGFR-mutated non-small cell…
Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI Kidney 3 Mins Read Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently…
M14TIL Trial: TIL Compared to Std. Ipilimumab [2022] Melanoma Skin Cancer Treatment 6 Mins Read M14TIL Trial: TIL Compared to Std. Ipilimumab [2022] This is the first experiment to use tumor-infiltrating lymphocytes (TIL) in metastatic…
